In a new study, scientists at La Jolla Institute for Immunology (LJI) compared the immune response of individuals who received older versus newer versions of the whooping cough vaccine. The unexpected findings may help explain the recent rise in whooping cough cases and point to potential targets for the next generation of vaccines.
Immune system researchers have designed a computational tool to boost pandemic preparedness. Scientists can use this new algorithm to compare data from vastly different experiments and better predict how individuals may respond to disease.
A new paper in Biology Methods & Protocols, published by Oxford University Press, shows it may be possible to design vaccines that will induce a stronger immune response to infecting pathogens, such as the virus causing COVID-19.
In the largest study of its kind, researchers from Children’s Hospital of Philadelphia (CHOP) used electronic health record (EHR) data from more than 200,000 pediatric patients to describe patterns of pediatric allergies across the United States, validating a population-level pattern of allergy development known as the “allergic march,” in which allergies first present as eczema, followed by food allergies, asthma, and environmental allergies. The researchers also found that a rare food allergy called eosinophilic esophagitis (EoE), which has historically been considered a disease affecting primarily White males, is more common among non-White patients than previously reported.
Animals and humans coexist with a vast array of microorganisms known as the microbiome, forming an intricate relationship that can range from mutually beneficial to pathogenic.
Not for public release
This news release is embargoed until 24-Jul-2023 5:00 PM EDT
Released to reporters: 18-Jul-2023 2:00 PM EDT
A reporter's PressPass is required to
access this story until the embargo expires on 24-Jul-2023 5:00 PM EDT
The Newswise PressPass gives verified journalists access to embargoed stories.
Please log in to complete a presspass application.
If you have not yet registered, please Register. When you
fill out the registration form, please identify yourself as a reporter in order to
advance to the presspass application form.
The widespread, pathogenic microbe Staphylococcus aureus can colonize the skin and mucous membranes throughout the body, particularly the vagina and gastrointestinal tract.
A new study, which involved experiments on mice and human patients, uncovered an important communication pathway between two molecules called CEACAM1 (CC1) and TIM-3, finding that the pathway plays a crucial role in controlling the body's immune response during liver transplantation.
University of Maryland School of Medicine (UMSOM) researchers engineered a new type of CAR T-cell therapy that, in preclinical studies, selectively attacked cancer cells while sparing healthy cells, potentially reducing the likelihood of toxic side effects from this innovative cancer treatment.
People who start taking medication soon after the first signs of multiple sclerosis (MS) may have a lower risk of disability later, according to a study published in the July 19, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology.
New research suggests that targeting autoimmune inflammation associated with amyotrophic lateral sclerosis (ALS) using two drugs, one of them already approved for multiple sclerosis, could be a promising approach for treatment.
The Cancer Research Institute awarded $28.7 million in research grants and fellowships in the 2023 fiscal year ending June 30, 2023. In total, CRI distributed 73 awards that will advance cancer immunology research at 41 institutions in 10 countries. CRI grants were awarded to support projects involving a variety of immune-based approaches as well as the development of novel technologies that may help pave the way for the next generation of immunotherapies.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Immune system changes in the pregnant body that protect the fetus appear to extend to the brain, where a decrease in immune cells late in gestation may factor into the onset of maternal behavior, new research in rats suggests.
People who contract COVID-19 but never develop symptoms – the so-called super dodgers – may have a genetic ace up their sleeve. They’re more than twice as likely as those who become symptomatic to carry a specific gene variation that helps them obliterate the virus, according to a new study led by UC San Francisco researchers.
A new study in mice suggests that having a common form of the flu during pregnancy may affect the next generation by impairing immune function in the gut. The study is published ahead of print in the American Journal of Physiology-Gastrointestinal and Liver Physiology.
A vaccine candidate that can protect children from Meningococcal group B (MenB), which can lead to meningitis, has progressed to clinical development, according to an announcement by researchers from the University of Surrey and the University of Oxford.
Systemic autoimmune diseases are characterized by inflammation of multiple organs and can have devastating consequences for patients. There is a dire need for treatments against these diseases.
CEPI to provide up to $4.98 USD million to Houston Methodist Research Institute-led consortium to use artificial intelligence for design of vaccines to fight diseases with pandemic potential. The project will support a consortium, led by HMRI, to design potential antigenic targets for up to 10 priority virus families with epidemic or pandemic potential. Laboratory-based tests will then be used to verify antigen designs for possible further development.
Rakuten Medical, Inc. (Rakuten Medical), a global biotechnology company developing and commercializing precision, cell-targeting photoimmunotherapy-based on its proprietary Alluminox™ platform, today announced it will host a virtual R&D Day on the preliminary safety and efficacy findings from its open-label Phase 1b/2 study of Alluminox™ treatment using ASP-1929 in combination with anti-PD-1 therapy in recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC).
Researchers have cracked how a particular type of immune cell develops in the body and protects against infection and disease. And the discovery could help in the development of more preventive treatments, according to a new study.
Giving patients with operable pancreatic cancers a three-pronged combination immunotherapy treatment consisting of the pancreatic cancer vaccine GVAX, the immune checkpoint therapy nivolumab and urelemab, an anti-CD137 agonist antibody treatment, is safe, it increases the amount of cancer-killing immune system T cells in the tumors and it appears effective when given two weeks prior to cancer-removal surgery, according to new research directed by Johns Hopkins investigators.
As a result of the COVID-19 pandemic, respiratory syncytial virus (RSV) surges in young children occurred outside the usual November to March season, when immune-based prophylactic is available to protect children at high risk for severe illness.
Breast cancer is the second leading cause of cancer mortality in women and the primary cause of cancer death among Hispanic women, according to the National Cancer Institute. The Center of Emphasis in Cancer focuses on forms of the disease prevalent in our majority-Hispanic Borderplex, seeking new strategies for the prevention and treatment of the deadly disease.
A multidisciplinary team led by Dr. Ángel R. Nebreda, Dr. María J. Macías and Dr. Modesto Orozco, all at IRB Barcelona, has developed a new type of p38 inhibitor, which preferentially impairs one of the activation pathways of this protein. In particular, these inhibitors block the self-activation (or autophosphorylation) of p38 but allow it to continue to be activated by other mechanisms.
New research suggests that targeting autoimmune inflammation associated with amyotrophic lateral sclerosis (ALS) using two drugs, one of them already approved for multiple sclerosis, could be a promising approach for treatment.
Scientists have long known that the immune system played a key role in our reactions to allergens and pathogens in the environment, but it was unclear whether it played any role in prompting these types of behaviors towards allergic triggers. According to Yale-led research published July 12 in the journal Nature, it turns out that the immune system plays a crucial role in changing our behaviors.
Together, Notre Dame's Paul Bohn and Joshua Shrout are searching for new ways to observe microorganisms like P. aeruginosa, moving beyond the traditional process of observing cell cultures grown in a Petri dish.
Though antibiotics can treat leprosy, researchers are concerned about the increase in drug-resistant strains. Now, a team reporting in ACS Central Science has begun to understand the role certain immune receptors play in leprosy, which could lead to new types of treatments for this disease.
A new analysis finds that up to millions of dollars could be saved annually on cancer immunotherapy treatments across the Veterans Health Administration by reconsidering how those drugs are delivered.
UT Southwestern Medical Center researchers have identified a gene called Lipe that appears to be pivotal to retinal health, with mutations spurring immune activation and retinal degeneration. This is important because the retina is responsible for detecting the light that is transformed into vision. The findings, published in Communications Biology, provide clues about the mechanisms behind a variety of disorders affecting the retina, including macular degeneration and diabetic retinopathy.
Through joint research with the Korea Institute of Machinery and Materials(KIMM), the Korea Research Institute of Bioscience and Biotechnology (KRIBB) developed a 3D bioprinting technology using natural killer cells (NK cells) as a new method of immunotherapy for treating cancer.
A Ludwig Cancer Research study has discovered that the presence of relatively high numbers of immune cells known as monocytes in tumors is linked to better outcomes in esophageal cancer patients treated with a combination of chemotherapy and immunotherapy, or immunochemotherapy.
With new cases of malaria being reported in Texas and Florida, researchers at UT Southwestern Medical Center continue to explore compounds for more effective drug-resistant therapies and biological targets to interfere with the parasites that spread the potentially fatal disease.
Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news. If you’re looking for resources who can comment on skin cancer awareness and skin protection during the summer months, see our list of experts and reach out to [email protected] to set up interviews.
In a new study, National Institutes of Health (NIH) researchers found that altered B cell function in children with mitochondrial disorders led to a weaker and less diverse antibody response to viral infections.
Prof. Pol.Capt. Pharm. Dr. Suchada Sukrong, lecturer at the Faculty of Pharmaceutical Sciences and a researcher at the Center of Excellence in DNA Barcoding of Thai Medicinal Plants, Chulalongkorn University, Dr. Kannika Thongkhao, and Pharm. Chayaphol Tangpatthong have won the gold medal and two Special Awards, namely the FIRI Award in the Best Invention category from “The first institute of inventors and researchers of Iran” (FIRI), Iran, and a Special Awards from “The Industrial Property Office of the Czech Republic the Czech Metallurgical Society,” The Czech Republic, in The 16th International Invention and Innovation Show (INTARG 2023) on May 24-25, 2023, at Katowice International Conference Center, Katowice, Republic of Poland, with their “Rapid DNA immunochromatographic assay for detection of toxic Aristolochia species, the plants responsible for aristolochic acid nephropathy”.
Researchers at Johns Hopkins Medicine, in collaboration with researchers at the National Institutes of Health, report that two new studies in mice with a humanized immune system and human cell lines have identified an enzyme that plays a critical role in the late stages of HIV replication.
Researchers continue to refine and improve targeted drug therapies that have changed the most common form of adult leukemia – from an incurable to a chronic condition. New data published in the New England Journal of Medicine offers another treatment option for patients who have stopped responding to the first and second generation drugs.
Nerve pathways in the spinal cord can be damaged or severed after an accident or serious injury, a condition known as paraplegia. Depending on where the injury is located, different parts of the body may be affected by deficits or paralysis.
Rutgers Cancer Institute of New Jersey has treated its first patient using genetically modified T-cells that were manufactured in its own state-of-the-art Good Manufacturing Practices (GMP) facility.
Scientists at St. Jude Children’s Research Hospital found that altering amounts of the nutrient glutamine in the tumor microenvironment could enhance or impair the immune system’s anti-cancer response.
Long Covid, which affects nearly two-million people in the UK (1), is not caused by an immune inflammatory reaction to COVID-19, University of Bristol-led research finds. Emerging data demonstrates that immune activation may persist for months after COVID-19.